PL3830085T3 - Deuterowane pochodne lanifibranoru - Google Patents

Deuterowane pochodne lanifibranoru

Info

Publication number
PL3830085T3
PL3830085T3 PL19759658.8T PL19759658T PL3830085T3 PL 3830085 T3 PL3830085 T3 PL 3830085T3 PL 19759658 T PL19759658 T PL 19759658T PL 3830085 T3 PL3830085 T3 PL 3830085T3
Authority
PL
Poland
Prior art keywords
lanifibranor
deuterated derivatives
deuterated
derivatives
Prior art date
Application number
PL19759658.8T
Other languages
English (en)
Inventor
Christian Montalbetti
Benaissa Boubia
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of PL3830085T3 publication Critical patent/PL3830085T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19759658.8T 2018-07-27 2019-07-26 Deuterowane pochodne lanifibranoru PL3830085T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1857021A FR3084254B1 (fr) 2018-07-27 2018-07-27 Derives deuteres du lanifibranor
PCT/FR2019/051860 WO2020021215A1 (fr) 2018-07-27 2019-07-26 Derives deuteres du lanifibranor

Publications (1)

Publication Number Publication Date
PL3830085T3 true PL3830085T3 (pl) 2024-04-15

Family

ID=63684156

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19759658.8T PL3830085T3 (pl) 2018-07-27 2019-07-26 Deuterowane pochodne lanifibranoru
PL23201458.9T PL4331584T3 (pl) 2018-07-27 2019-07-26 Zastosowania lecznicze deuterowanych pochodnych lanifibranoru

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL23201458.9T PL4331584T3 (pl) 2018-07-27 2019-07-26 Zastosowania lecznicze deuterowanych pochodnych lanifibranoru

Country Status (19)

Country Link
US (2) US12291526B2 (pl)
EP (2) EP4331584B1 (pl)
JP (2) JP7434278B2 (pl)
CN (1) CN112638911B (pl)
DK (2) DK3830085T3 (pl)
ES (2) ES3014955T3 (pl)
FI (2) FI3830085T3 (pl)
FR (1) FR3084254B1 (pl)
HR (2) HRP20240157T1 (pl)
HU (2) HUE065045T2 (pl)
LT (2) LT4331584T (pl)
MA (1) MA67726B1 (pl)
MD (1) MD4331584T2 (pl)
PL (2) PL3830085T3 (pl)
PT (2) PT3830085T (pl)
RS (2) RS66614B1 (pl)
SI (2) SI4331584T1 (pl)
SM (2) SMT202400053T1 (pl)
WO (1) WO2020021215A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102199640B1 (ko) * 2020-01-06 2021-01-07 브렉소젠 주식회사 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물
EP4000616A1 (en) * 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022143479A1 (zh) * 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AU2023451460A1 (en) 2023-06-06 2026-01-15 Inventiva Use of ck18m65, hyaluronic acid, fructosamine and alt for monitoring of liver disease treatment with lanifibranor
KR20260016549A (ko) 2023-06-06 2026-02-03 엥방티바 라니피브라노르를 이용한 간 질환 치료를 모니터링하기 위한 아디포넥틴, 페리틴, mmp9 및 트랜스페린의 용도
AR133887A1 (es) 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
CA2951337C (en) * 2014-06-13 2022-08-23 Inventiva Ppar compounds for use in the treatment of fibrotic diseases
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
WO2018039521A1 (en) 2016-08-26 2018-03-01 Concert Pharmaceuticals, Inc. Deuterated cenicriviroc
US11504380B2 (en) * 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis

Also Published As

Publication number Publication date
CN112638911B (zh) 2024-07-19
FI4331584T3 (fi) 2025-04-01
FR3084254B1 (fr) 2020-10-23
MA67726B1 (fr) 2025-04-30
JP7637281B2 (ja) 2025-02-27
SI4331584T1 (sl) 2025-04-30
HRP20250340T1 (hr) 2025-05-09
DK4331584T3 (da) 2025-03-17
JP7434278B2 (ja) 2024-02-20
EP4331584A1 (fr) 2024-03-06
EP3830085A1 (fr) 2021-06-09
EP4331584B1 (fr) 2025-01-01
JP2021533101A (ja) 2021-12-02
ES3014955T3 (en) 2025-04-28
US20210300913A1 (en) 2021-09-30
PL4331584T3 (pl) 2025-04-28
DK3830085T3 (da) 2024-01-22
HUE065045T2 (hu) 2024-04-28
SMT202500113T1 (it) 2025-05-12
US12291526B2 (en) 2025-05-06
HRP20250340T8 (hr) 2025-06-20
SI3830085T1 (sl) 2024-03-29
RS66614B1 (sr) 2025-04-30
LT3830085T (lt) 2024-02-12
PT4331584T (pt) 2025-02-27
LT4331584T (lt) 2025-03-25
JP2024036611A (ja) 2024-03-15
MD4331584T2 (ro) 2025-11-30
US20250263406A1 (en) 2025-08-21
PT3830085T (pt) 2024-01-24
HRP20240157T1 (hr) 2024-04-12
FI3830085T3 (fi) 2024-01-17
FR3084254A1 (fr) 2020-01-31
CN112638911A (zh) 2021-04-09
EP3830085B1 (fr) 2023-11-08
HUE070489T2 (hu) 2025-06-28
RS65095B1 (sr) 2024-02-29
WO2020021215A1 (fr) 2020-01-30
ES2970597T3 (es) 2024-05-29
SMT202400053T1 (it) 2024-03-13

Similar Documents

Publication Publication Date Title
PT4331584T (pt) Utilizações terapêuticas de derivados deuterados do lanifibranor
IL279468A (en) Crystallographic modifications of odeviccibat
IL272888B1 (en) Uses of piperidinyl-indole derivatives
SMT202100472T1 (it) Sintesi di omecamtiv mecarbil
IL276592A (en) History of Subtirum
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
SG11202012594RA (en) Spirochromane derivatives
GB2573065B (en) Optimization of ranging measurements
PL3796975T3 (pl) Pochodne sulfonyloaminobenzamidu
ZA202105399B (en) Use of spiropidion
PL3770162T3 (pl) Pochodne dihydrochromenu
ZA202104656B (en) Deuterated forms and derivatives of volinanserin
SG11202105136WA (en) Application of chidamide
SG11202101817UA (en) Methods of inhibition
PT3901141T (pt) Nova forma de isoquinolinossulfonamida
HK40054945A (en) Deuterated analogs of acetyl-leucine
GB201820685D0 (en) Synthesis of 8-chloroadenosine derivatives
ZA202200181B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
GB201810835D0 (en) Methods of use
IL260405A (en) None-abusive derivatives of ritalin
GB201807468D0 (en) Methods of synthesis
GB201806948D0 (en) Derivatives
GB201721386D0 (en) Chrondogy of time-wave
PT3511335T (pt) Fabrico de metalassilsesquioxanos